BGB-30813 / BeOne Medicines - LARVOL DELTA

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Terminated | Sponsor: BeiGene | Trial completion date: Dec 2025 ➔ Aug 2025 | Active, not recruiting ➔ Terminated; The Sponsor has made the decision to discontinue the clinical development of BGB-30813 and close the study based on imbalanced benefit/risk profile in the BGB-A317-30813-101 study.

dMMR • MSI-H • Trial completion date • Trial termination • Tumor mutational burden • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Dec 2026 ➔ Dec 2025 | Trial primary completion date: Dec 2026 ➔ Aug 2025

dMMR • MSI-H • Trial completion date • Trial primary completion date • Tumor mutational burden • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting | N=200 ➔ 44

dMMR • Enrollment change • Enrollment closed • MSI-H • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: BeiGene | Active, not recruiting ➔ Recruiting | N=37 ➔ 200 | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: May 2025 ➔ Dec 2026

Combination therapy • Enrollment change • Enrollment open • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting | N=209 ➔ 37

Combination therapy • Enrollment change • Enrollment closed • Metastases • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov) - P1 | N=209 | Recruiting | Sponsor: BeiGene | Phase classification: P1a/1b ➔ P1

Combination therapy • Metastases • Phase classification • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov) - P1a/1b | N=289 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov) - P1a/1b | N=289 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • Metastases • New P1 trial • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • MSI • TMB